	The Prophylactic Role of Hyperthermic Intraperitoneal Chemotherapy on Spontaneously Ruptured Hepatocellular Carcinoma with Radical Resection: A Retrospective Study. Cancer Manag Res Li Z, Lin J, Gao K, Dang X, Hua Y. PMID: 41459137 [PubMed]
	Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis. Can J Gastroenterol Hepatol Guo H, Li Y, Liu B, Liu S. PMID: 41458898 [PubMed - indexed for MEDLINE]
	Efficacy of TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol Ye K, Zhou J, Lin J, Li Y, Luo Y, Xie F. PMID: 41458593 [PubMed]
	Metabolic signatures in gastroenteropancreatic neuroendocrine neoplasms: unraveling diagnostic and prognostic insights. Front Endocrinol (Lausanne) de Lima-Souza RA, Maciel TF, Gonçalves MWA, Ribeiro FCP, Maioral RA, Scarini JF, Soraes HP, Fillmore GC, Egal ESA. PMID: 41458541 [PubMed - indexed for MEDLINE]
	The Role of RANBP3L in Pan-Cancer With Its Significance in Hepatocellular Carcinoma. Cancer Rep (Hoboken) Cen B, Li J, Wang C. PMID: 41457788 [PubMed - indexed for MEDLINE]
	MTAP in small biopsy samples of pancreatic lesions: a potential diagnostic biomarker. Immunohistochemical, fluorescence in situ hybridization and molecular analysis. Pathologica Lucà S, Salzillo C, Masola V, De Vita F, Porpora D, Conzo G, Savarese G, Sirica R, Cozzolino I, Clery E, Zito Marino F, Franco R, Montella M. PMID: 41454767 [PubMed - indexed for MEDLINE]
	High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Ann Surg Oncol Fujita K, Okamura Y, Hayashi M, Ashida R, Otsu T, Sakai A, Mii S, Sugimoto M, Yamamoto N, Toyama H, Maeda A, Mizuno N, Yokoyama Y, Yamaguchi J, Nakagawa N, Kurimoto K, Tanaka H, Takami H, Enomoto A, Uesaka K, Kanda M. PMID: 41454190 [PubMed - as supplied by publisher]
	Advancement in preclinical development of cancer treatment agents through modulation of Rac1: From EHop-016 to natural products. Biochim Biophys Acta Rev Cancer Liu Y, Wong SN, Lyu A, Ko JK. PMID: 41453624 [PubMed - as supplied by publisher]
	The Emerging Triad in Cancer and Aging: Cellular Senescence, Microbiome, and Tumor Microenvironment. Aging Dis Gong X, Wang S, Xia Q. PMID: 41452713 [PubMed - as supplied by publisher]
	"Exosomal blueprint of lung-tropic metastasis: molecular signatures, microenvironmental conditioning, and translational implications in cancer". Med Oncol Ebrahim NAA, Farghaly TA, Soliman SMA. PMID: 41452573 [PubMed - indexed for MEDLINE]
	Ethical challenges and governance of artificial intelligence in hepatocellular carcinoma management : Wan DL et al. Ethical considerations in AI for hepatocellular carcinoma. Med Oncol Wan DL, Lin SZ. PMID: 41452505 [PubMed - indexed for MEDLINE]
	The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Lancet Oncol Janssen QP, van Dam JL, Besselink MG, Wilmink JW, Homs MYV, van Tienhoven G, van Eijck CHJ, Groot Koerkamp B. PMID: 41449160 [PubMed - in process]
	The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Lancet Oncol Sherry AD, Jethwa KR, Msaouel P, Ludmir EB. PMID: 41449158 [PubMed - in process]
	The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Lancet Oncol Neoptolemos JP, Springfeld C, Öhlund D, Büchler MW, Michalski CW. PMID: 41449156 [PubMed - in process]
	First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. Lancet Oncol Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li S, Cha E, Kalaitzidou M, Huang X, Allen S, Hsu CH. PMID: 41449151 [PubMed - indexed for MEDLINE]
	A Phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Cancer Lett Horvat NK, Diab M, Phillips MJ, Veal-McCook A, Grundy EE, Alese OB, Greene E, Gbolahan O, Coleman K, Doxie D, Herting CJ, Hammons J, Mahdi Z, Switchenko JM, Paulos CM, El-Rayes BF, Lesinski GB. PMID: 41448449 [PubMed - as supplied by publisher]
	From diagnosis and treatment to prognosis: Clinical prospects of artificial intelligence in multimodal research of hepatocellular carcinoma. Crit Rev Oncol Hematol Jia W, Duan X, Yao Q, Liu R, Cheng CL. PMID: 41448299 [PubMed - as supplied by publisher]
	Transcatheter Arterial Chemoembolization May Be Selectively Indicated as Postoperative Adjuvant Therapy for Hepatocellular Carcinoma Patients with Microvascular Invasion. J Hepatocell Carcinoma Zeng J, Huang H, Tang M, Tao Z, Mo K, Chen W, Su Y, Su J, Liang R, Lin Y, Li L, Wu G, Luo X, Ye J, Mai R. PMID: 41446352 [PubMed]
	Organ-specific role of neutrophil extracellular traps in shaping the postoperative thrombo-inflammatory niche in pancreatic ductal adenocarcinoma: a multi-model machine learning and mechanistic study. Front Immunol Cui S, Wang D, Lyu S, Huang J, Lang R, Wang J. PMID: 41445740 [PubMed - indexed for MEDLINE]
	Integrated transcriptome study reveals a stress response state CD4â€‰+T cells related to immune tolerance in breast cancer. Breast Cancer Res Gu J, Qi Q, Mao X, Cong R, Sun Y, Tang X, Guan X, Wang J, Yu M, Wang S, Pan H, Zhang K, Qiu W, Li W, Wang C, Zhou W. PMID: 41444999 [PubMed - as supplied by publisher]

Articles 1 - 20 / 58593

Page 1 of 2930



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy